Performance of an Idiopathic Pulmonary Fibrosis–Derived Multibiomarker Panel for Rheumatoid Arthritis–Associated Interstitial Lung Disease
Authors' conclusion
A multibiomarker panel derived from IPF-associated biomarkers was associated with RA-ILD in separate development and validation cohorts.
Study context
- Population
- Patients with rheumatoid arthritis (RA): two development cohorts and an independent multicenter prospective cohort of US veterans with RAvalidation cohort
- Participants
- 2,507 patients
- Comparison
- Highest vs lowest quartile of idiopathic pulmonary fibrosis (IPF) multibiomarker score
- Outcome
- Association of IPF multibiomarker score with prevalent and incident ILD
Methodological detailsthree independent cohorts, multicenter prospective validation cohort, multivariable regression
- Three independent cohorts
- Multicenter prospective validation cohort
- Multivariable regression
Performance
As reported in the abstract
Highest quartile vs Lowest quartileEstimate (95% CI)
Prevalent ILD
aOR 2.14(1.18–3.87)
Incident ILD
aHR 2.45(1.55–3.88)
Further findings
- Cumulative hazard of incident interstitial lung disease (ILD) · 15 years — Highest quartile
- 20%
- Cumulative hazard of incident ILD — All other quartiles
- <10%
- Cumulative hazard of incident ILD: approached 20%
Prevalent RA-ILD, development cohorts (n = 93 and n = 71)
- RA-ILD had significantly higher IPF multibiomarker scores than RA alone in both development cohorts
Original publication
Performance of an Idiopathic Pulmonary Fibrosis–Derived Multibiomarker Panel for Rheumatoid Arthritis–Associated Interstitial Lung Disease. Arthritis Rheumatol. Published 11 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →